Abstract
Myelodysplastic syndromes (MDS) are a group of clonal disturbances with defective cellular differentiation. Vitamin D3 (VD) analogues can act on the differentiation and maturity of different cell lines. We studied the effects of VD on a series of patients with MDS in an open-design trial. Nineteen patients, 12 men and seven women, with MDS were included. Patients were 74:8 ± 5.6 years (mean ± SD), seven had refractory anaemic with ringed sideroblasts, five had refractory anaemia, one had refractory anaemia with excess of blasts and six had chronic myelomonocytic leukaemia. All the patients were in a low to intermediate risk group. Mean follow-up period was 26°21 months, range 9-75. Responders were defined as follows: granulocyte or platelet count increase by 50%, or haemoglobin increase of 1.5 g/dl or transfusion needs decrease by 50%. The first five patients received 266μg of calcifediol three times a week and the other 14 received calcitriol (0.25- 0.75 μg/d). Response was observed in 11 patients. In the calcifediol- treated group, one case responded, three were non-responders, and one showed progression. In the calcitriol group, 10 were responders (two with major response), and four were non-responders. No correlation was observed between baseline levels of vitamin D metabolites and the presence of response. No hypercalcaemia was observed. Treatment with vitamin D3 metabolites could induce a long-standing response of the haematological disturbance in some low-intermediate risk MDS patients without inducing hypercalcaemia.
| Original language | English |
|---|---|
| Pages (from-to) | 516-520 |
| Number of pages | 5 |
| Journal | British Journal of Haematology |
| Volume | 100 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1998 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
Cite this
Vitamin D treatment in myelodysplastic syndromes. / Mellibovsky, L.; Díez, A.; Pérez-Vila, E.; Serrano, S.; Nacher, M.; Aubía, J.; Supervía, A.; Recker, Robert R.
In: British Journal of Haematology, Vol. 100, No. 3, 1998, p. 516-520.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vitamin D treatment in myelodysplastic syndromes
AU - Mellibovsky, L.
AU - Díez, A.
AU - Pérez-Vila, E.
AU - Serrano, S.
AU - Nacher, M.
AU - Aubía, J.
AU - Supervía, A.
AU - Recker, Robert R.
PY - 1998
Y1 - 1998
N2 - Myelodysplastic syndromes (MDS) are a group of clonal disturbances with defective cellular differentiation. Vitamin D3 (VD) analogues can act on the differentiation and maturity of different cell lines. We studied the effects of VD on a series of patients with MDS in an open-design trial. Nineteen patients, 12 men and seven women, with MDS were included. Patients were 74:8 ± 5.6 years (mean ± SD), seven had refractory anaemic with ringed sideroblasts, five had refractory anaemia, one had refractory anaemia with excess of blasts and six had chronic myelomonocytic leukaemia. All the patients were in a low to intermediate risk group. Mean follow-up period was 26°21 months, range 9-75. Responders were defined as follows: granulocyte or platelet count increase by 50%, or haemoglobin increase of 1.5 g/dl or transfusion needs decrease by 50%. The first five patients received 266μg of calcifediol three times a week and the other 14 received calcitriol (0.25- 0.75 μg/d). Response was observed in 11 patients. In the calcifediol- treated group, one case responded, three were non-responders, and one showed progression. In the calcitriol group, 10 were responders (two with major response), and four were non-responders. No correlation was observed between baseline levels of vitamin D metabolites and the presence of response. No hypercalcaemia was observed. Treatment with vitamin D3 metabolites could induce a long-standing response of the haematological disturbance in some low-intermediate risk MDS patients without inducing hypercalcaemia.
AB - Myelodysplastic syndromes (MDS) are a group of clonal disturbances with defective cellular differentiation. Vitamin D3 (VD) analogues can act on the differentiation and maturity of different cell lines. We studied the effects of VD on a series of patients with MDS in an open-design trial. Nineteen patients, 12 men and seven women, with MDS were included. Patients were 74:8 ± 5.6 years (mean ± SD), seven had refractory anaemic with ringed sideroblasts, five had refractory anaemia, one had refractory anaemia with excess of blasts and six had chronic myelomonocytic leukaemia. All the patients were in a low to intermediate risk group. Mean follow-up period was 26°21 months, range 9-75. Responders were defined as follows: granulocyte or platelet count increase by 50%, or haemoglobin increase of 1.5 g/dl or transfusion needs decrease by 50%. The first five patients received 266μg of calcifediol three times a week and the other 14 received calcitriol (0.25- 0.75 μg/d). Response was observed in 11 patients. In the calcifediol- treated group, one case responded, three were non-responders, and one showed progression. In the calcitriol group, 10 were responders (two with major response), and four were non-responders. No correlation was observed between baseline levels of vitamin D metabolites and the presence of response. No hypercalcaemia was observed. Treatment with vitamin D3 metabolites could induce a long-standing response of the haematological disturbance in some low-intermediate risk MDS patients without inducing hypercalcaemia.
UR - http://www.scopus.com/inward/record.url?scp=0031864278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031864278&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.1998.00598.x
DO - 10.1046/j.1365-2141.1998.00598.x
M3 - Article
VL - 100
SP - 516
EP - 520
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 3
ER -